Geron (GERN) Cash & Current Investments (2010 - 2026)
Geron's (GERN) quarterly Cash & Current Investments came in at $300.8 million in Q2 2026, down 22.46% year-over-year from $388.0 million in Q2 2025, and down 3.7% quarter-over-quarter from $312.4 million in Q1 2026.
Analysis
Geron (GERN) Cash & Current Investments (2010 - 2026) Analysis & Trends
Geron has disclosed Cash & Current Investments across 17 years of filings, most recently posting $300.8 million for Q2 2026.
- In Q2 2026, Cash & Current Investments fell 22.46% year-over-year to $300.8 million; the TTM figure through Jun 2026 stood at $300.8 million (down 22.46% YoY), while the FY2025 annual figure was $357.9 million, down 11.97% from the prior year.
- Cash & Current Investments came in at $300.8 million for Q2 2026 at Geron, down from $312.4 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $443.0 million in Q1 2024 to a low of $166.7 million in Q1 2022.
- Average Cash & Current Investments over 5 years is $324.5 million, with a median of $348.8 million recorded in 2024.
- Year-over-year, Cash & Current Investments jumped 128.44% in 2023 and slipped 22.46% in 2026.
- Over 5 years, Cash & Current Investments stood at $172.7 million in 2022, then jumped by 93.17% to $333.7 million in 2023, then grew by 21.84% to $406.6 million in 2024, then retreated by 11.97% to $357.9 million in 2025, then slipped by 15.94% to $300.8 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $300.8 million in Q2 2026, $312.4 million in Q1 2026, and $357.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.85 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 5.18 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.14 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 300.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300.85 Mn |
| Mar 31, 2026 | 312.40 Mn |
| Dec 31, 2025 | 357.92 Mn |
| Sep 30, 2025 | 380.53 Mn |
| Jun 30, 2025 | 387.98 Mn |
| Mar 31, 2025 | 396.88 Mn |
| Dec 31, 2024 | 406.57 Mn |
| Sep 30, 2024 | 339.77 Mn |
| Jun 30, 2024 | 362.73 Mn |
| Mar 31, 2024 | 443.05 Mn |
| Dec 31, 2023 | 333.70 Mn |
| Sep 30, 2023 | 313.53 Mn |
| Jun 30, 2023 | 371.38 Mn |
| Mar 31, 2023 | 380.74 Mn |
| Dec 31, 2022 | 172.75 Mn |
| Sep 30, 2022 | 194.79 Mn |
| Jun 30, 2022 | 219.29 Mn |
| Mar 31, 2022 | 166.67 Mn |
| Dec 31, 2021 | 183.72 Mn |
| Sep 30, 2021 | 176.12 Mn |